Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BRIM-3 in previously untreated BRAF V600E-mutant unresectable or metastatic melanoma
2009-012293-12Phase 3Completed
- Sponsor
- Roche
- Start
- Oct 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in melanoma comparing Vemurafenib with Dacarbazine (2 arms). Primary endpoints: Progression-free survival and Overall survival. Started Oct 2009; status: completed.
02
Drugs
vemurafenibdacarbazine
03
Conditions
melanoma
Beyond the preview
Go deeper on 2009-012293-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-012293-12.